# Nurix Therapeutics (stock symbol: NRIX) Logo in transparent PNG and SVG formats

## Nurix Therapeutics Logo large

### Nurix Therapeutics Logo large Download PNG (50.72 KB)

![Nurix Therapeutics Logo large Download PNG (50.72 KB)](/img/orig/NRIX_BIG-b8a9b218.png)

### Nurix Therapeutics Logo large Download SVG (2.68 KB)

![Nurix Therapeutics Logo large Download SVG (2.68 KB)](/img/orig/NRIX_BIG-67897afd.svg)

## Nurix Therapeutics Logo icon format

### Nurix Therapeutics Logo icon format Download PNG (22.46 KB)

![Nurix Therapeutics Logo icon format Download PNG (22.46 KB)](/img/orig/NRIX-b7f59aa6.png)

### Nurix Therapeutics Logo icon format Download SVG (941 Bytes)

![Nurix Therapeutics Logo icon format Download SVG (941 Bytes)](/img/orig/NRIX-173f37f6.svg)

## Nurix Therapeutics Logo large for dark backgrounds

### Nurix Therapeutics Logo large for dark backgrounds Download PNG (49.44 KB)

![Nurix Therapeutics Logo large for dark backgrounds Download PNG (49.44 KB)](/img/orig/NRIX_BIG.D-20066aed.png)

### Nurix Therapeutics Logo large for dark backgrounds Download SVG (2.68 KB)

![Nurix Therapeutics Logo large for dark backgrounds Download SVG (2.68 KB)](/img/orig/NRIX_BIG.D-341423c1.svg)

## About Nurix Therapeutics

Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It also develops NX-0255, a CBL-B inhibitor for ex vivo use to enhance adoptive T-cell therapy; and DeTIL-0255 that is in the Phase 1 clinical trial for the treatment of gynecologic cancers, including ovarian, endometrial, and cervical cancer. The company has a strategic collaboration agreement with Gilead Sciences, Inc. for cancer and other challenging diseases patients; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. The company was incorporated in 2009 and is headquartered in San Francisco, California.

1. Website domain: nurixtx.com
2. Employees: 242
3. Marketcap: $0.45 Billion USD


## Categories
- [x] ðŸ‡ºðŸ‡¸ United States
- [x] ðŸ’Š Pharmaceuticals
- [x] ðŸ§¬ Biotech
